Accessibility Menu
Pmgc logo

Pmgc(NASDAQ) ELAB

Market Cap$4.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-100%
5 YearN/A
1 Year-100%
1 Month-47%
$5.23
+2.75%
+0.14Today
Pmgc last closing stock price
MetricPriceDate
Last closeUSD 5.232026-09-03
Pmgc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.29%USD 5.832026-08-27
1 month-46.83%USD 9.842026-08-04
3 month-66.04%USD 15.402026-06-05
Year to date-98.53%USD 355.202025-12-31
1 year-99.55%USD 1,161.602025-09-03
Since inception-100%USD 3,998,588.732023-11-21

Pmgc Financials at a Glance

Market Cap

$4.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.58M

Net Income (TTM)

-$13.49M

EPS (TTM)

-$1,815.13

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.99 (High)

Price

$5.23

Volume

921

Open

$5.16

Previous Close

$5.23

Daily Range

$5.01 - $5.39

52-Week Range

$4.97 - $2,671.20

Estimated Earnings Date

May 13, 2026

ELAB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pmgc

PMGC develops medicines and invests in healthcare companies. Its main product helps people lose weight while keeping muscle. The company also researches new treatments and invests in other businesses.

Products and Services

  • Biopharmaceuticals: Develops EL-22, a probiotic to help preserve muscle during weight loss treatments. (0% of revenue in Q2 2025)
  • Medical Research: Conducts scientific research and development, often with Canadian university partners. (0% of revenue in Q2 2025)
  • Investment Operations: Invests in and acquires other companies, focusing on healthcare and related sectors. (0% of revenue in Q2 2025)
  • Discontinued Skincare: Previously sold skincare products, but exited this business in January 2025. (100% of prior revenue)

Growth and Expansion

  • Sold skincare business in January 2025 to focus on new strategy.
  • Acquired exclusive rights to EL-22, including animal health uses, in March 2025.
  • Bought Pacific Sun Packaging and AGA Precision Systems in July 2025 to expand into packaging and manufacturing.
  • Formed partnerships with Canadian universities for research grants and development support.

What Makes PMGC Stand Out

PMGC uses a holding company model, combining drug development, research, and investment. It leverages Canadian research grants to lower costs. The company actively acquires businesses to diversify its portfolio.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2024.
  • Operating expenses were $1.01 million in Q2 2025, up from $556,242 in Q2 2024.
  • Net loss from continuing operations was $579,490 in Q2 2025.
  • Cash balance reached $5.68 million as of June 30, 2025.

Bottom Line

PMGC has shifted from skincare to a diversified healthcare and investment model. The company now focuses on drug development, research, and acquiring new businesses.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

34

CEO

Graydon Bensler, CFA

Website

www.pmgcholdings.com

Headquarters

Newport Beach, CA 92660, US

ELAB Financials

Key Financial Metrics (TTM)

Gross Margin

10.31%

Operating Margin

-477.02%

Net Income Margin

-522.97%

Return on Equity

-118.11%

Return on Capital

-70.37%

Return on Assets

-36.88%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

809.60K

Volume

921

Avg. Volume

265.12K

Financials (TTM)

Gross Profit

$265.76K

Operating Income

-$12.30M

EBITDA

-$11.97M

Operating Cash Flow

-$8.21M

Capital Expenditure

-$777.77K

Free Cash Flow

-$8.99M

Cash & ST Invst.

$18.79M

Total Debt

$13.92M

Pmgc Performance Analysis

Pmgc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 766,27792557.4%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 590,084N/A
Pmgc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-316.4%
Q12026-02-28124.2%
Q22026-06-3091.6%
Pmgc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -222,181.68317.2%
20232023-12-31USD -470,741.04111.9%
20242024-12-31USD -65,924.62-86.0%
20252025-12-31USD -3,787.42-94.3%
Pmgc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-210.8%
Q42025-12-3155.9%
Q12026-02-2878.5%
Q22026-06-3094.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.31M

N/A

Gross Profit

$104.45K

+522370.0%

Gross Margin

7.99%

N/A

Market Cap

$4.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$128.31K

N/A

Employees

33

N/A

Net Income

-$2.94M

-423.0%

EBITDA

-$3.51M

-506.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$18.79M

+197.9%

Total Debt

$13.92M

N/A

Accounts Receivable

$603.49K

+195.4%

Inventory

$932.51K

N/A

Long Term Debt

$4.19M

N/A

Short Term Debt

$9.72M

N/A

Return on Assets

-36.88%

N/A

Return on Invested Capital

-57.92%

N/A

Free Cash Flow

-$1.96M

-45.6%

Operating Cash Flow

-$1.99M

-47.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLECMoolec Science S.A.
$7.14+6.09%
ATXIAvenue Therapeutics, Inc.
$0.57+9.62%
NCELNewcelX Ltd.
$3.35+0.00%
DRMADermata Therapeutics, Inc.
$1.23-3.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$106.74+0.00%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$51.60-0.00%
IBITiShares Bitcoin Trust
$46.35+0.06%

Questions About ELAB

What is the current price of Pmgc?

Pmgc is trading at $5.23 per share.

What is the 52-week range for Pmgc?

Over the past 52 weeks, Pmgc has traded between $4.97 and $2,671.20.

How much debt does Pmgc have?

As of the most recent reporting period, Pmgc reported total debt of $14.24M.

How much cash does Pmgc have on hand?

Pmgc reported $18.14M in cash and cash equivalents in its most recent financial results.

What is Pmgc’s dividend yield?

Pmgc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services